Anavex Life Sciences (AVXL) Stock Forecast & Price Target

$6.74

-0.10 (-1.46%)

(As of 07/26/2024 ET)

Anavex Life Sciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Strong Buy
Based on 2 Analyst Ratings

Based on 2 Wall Street analysts who have issued ratings for Anavex Life Sciences in the last 12 months, the stock has a consensus rating of "Strong Buy." Out of the 2 analysts, 1 has given a buy rating, and 1 has given a strong buy rating for AVXL.

Consensus Price Target

$40.00
493.47% Upside

High Forecast	$40.00
Average Forecast	$40.00
Low Forecast	$40.00

According to the 2 analysts' twelve-month price targets for Anavex Life Sciences, the average price target is $40.00. The highest price target for AVXL is $40.00, while the lowest price target for AVXL is $40.00. The average price target represents a forecasted upside of 493.47% from the current price of $6.74.

Type	Current Forecast 7/27/23 to 7/26/24	1 Month Ago 6/27/23 to 6/26/24	3 Months Ago 4/28/23 to 4/27/24	1 Year Ago 7/27/22 to 7/27/23
Consensus Rating	Strong Buy	Buy	Buy	Moderate Buy
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	2 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$40.00	$40.00	$40.00	$43.25
Forecasted Upside	493.47% Upside	955.41% Upside	561.70% Upside	355.06% Upside

Get Anavex Life Sciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.

Ad Crypto 101 Media

Brace Yourself: Experts calling for Bitcoin to hit $100k

For the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.

Click here to get The Crypto Bull Run Millionaire Blueprint now.

AVXL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AVXL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Anavex Life Sciences Stock vs. The Competition

Type	Anavex Life Sciences	Medical Companies	S&P 500
Consensus Rating Score	3.50	2.72	2.50
Consensus Rating	Strong Buy	Moderate Buy	Moderate Buy
Predicted Upside	493.47% Upside	3,123.46% Upside	9.17% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/22/2024	EF Hutton Acquisition Co. I 1 of 5 stars	J. Kolbert Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/11/2024	HC Wainwright 3 of 5 stars		Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00	+955.41%
2/9/2023	BTIG Research 2 of 5 stars		Lower Target	Buy	$35.00 ➝ $28.00	+156.18%
12/6/2022	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Duncan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$16.00 ➝ $11.00	+14.82%
12/2/2022	Jonestrading Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$40.00 ➝ $80.00	+801.92%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 09:55 PM ET.

AVXL Forecast - Frequently Asked Questions

What is Anavex Life Sciences' forecast for 2024?: According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Anavex Life Sciences is $40.00, with a high forecast of $40.00 and a low forecast of $40.00.
Should I buy or sell Anavex Life Sciences stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last year. There is currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "strong buy" AVXL shares.
Does Anavex Life Sciences's stock price have much upside?: According to analysts, Anavex Life Sciences's stock has a predicted upside of 955.41% based on their 12-month stock forecasts.
Has Anavex Life Sciences been upgraded by Wall Street analysts recently?: Over the previous 90 days, Anavex Life Sciences's stock had 1 upgrade by analysts.
What analysts cover Anavex Life Sciences?: Anavex Life Sciences has been rated by research analysts at EF Hutton Acquisition Co. I, and HC Wainwright in the past 90 days.
Do Wall Street analysts like Anavex Life Sciences more than its competitors?: Analysts like Anavex Life Sciences more than other "medical" companies. The consensus rating for Anavex Life Sciences is Strong Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AVXL compares to other companies.